★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets More FDA Approvals Arise in Gene Editing Space, Renewed VC Rounds Begin to Ramp Up Shares of biotech firms focused on gene editing have been heating up this month, largely on the back of the…McAlinden Research PartnersMay 25, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene Editing FDA Approvals for Genetic Medicines Speed Ahead Despite Recent Setbacks in Base Editing Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…McAlinden Research PartnersDecember 8, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingⓁ PharmaceuticalsMarkets Pharma Fires Up More M&A Deals in Genetic Medicine as First CRISPR Drug Moves Closer to Commercialization Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…McAlinden Research PartnersOctober 19, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets CRISPR Tech Closes in on First FDA Approval, New Treatment Methods Continue to Emerge The US's first marketed CRISPR drug may be set to make its debut in a year or less, following CRISPR…McAlinden Research PartnersSeptember 29, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets CRISPR Closing in on First US Product Launch, Latest Data Shows Treatment 100% Effective After Three Years A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…McAlinden Research PartnersJuly 11, 2022